XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,867,151 | +529.2% | 171,755 | +609.1% | 1.88% | +440.6% |
| Q2 2023 | $932,509 | -88.2% | 24,221 | -89.1% | 0.35% | -85.6% |
| Q1 2023 | $7,935,717 | +115.6% | 221,730 | +137.5% | 2.42% | +62.3% |
| Q4 2022 | $3,681,000 | -24.1% | 93,364 | -30.5% | 1.49% | +11.9% |
| Q3 2022 | $4,849,000 | -4.2% | 134,331 | -19.3% | 1.33% | -35.8% |
| Q2 2022 | $5,062,000 | +547.3% | 166,399 | +564.5% | 2.07% | +573.1% |
| Q4 2021 | $782,000 | -80.6% | 25,043 | -90.5% | 0.31% | -80.8% |
| Q3 2021 | $4,036,000 | – | 264,134 | – | 1.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
| COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
| TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
| Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
| Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
| GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
| DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
| Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
| Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
| Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |